Who
David J. Mazzo
President & CEO
Company insider
Files Form 4 as: President & CEO, Lisata Therapeutics; Director, Palisade Bio; Director, EyePoint; Director, Avanir Pharmaceuticals; Chief Executive Officer, Regado Biosciences.
In numbers
- Trades disclosed
- 132
- Buys
- 2
- Sells
- 0
- Bought
- $44K
- Sold
- $0
- Companies
- 5
- Companies where not an officer
- 3
- First trade
- 13 Feb 2006
- Last trade
- 9 Jan 2026
- Last filed
- 13 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Jan 2026filed 13 Jan 2026 | LSTA Lisata TherapeuticsBiotechnology | SEC FORM 4 Code A | —81,000 at $0.00 | filing |
| 9 Jan 2026filed 13 Jan 2026 | LSTA Lisata TherapeuticsBiotechnology | SEC FORM 4 Code F | $21K10,503 at $1.97 | filing |
| 9 Jan 2026filed 13 Jan 2026 | LSTA Lisata TherapeuticsBiotechnology | SEC FORM 4 Code F | $21K10,515 at $1.97 | filing |
| 9 Jan 2026filed 13 Jan 2026 | LSTA Lisata Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 9 Jan 2026filed 13 Jan 2026 | LSTA Lisata TherapeuticsBiotechnology | SEC FORM 4 Code F | $24K12,224 at $1.97 | filing |
| 9 Jan 2026filed 13 Jan 2026 | LSTA Lisata TherapeuticsBiotechnology | SEC FORM 4 Code F | $15K7,854 at $1.97 | filing |
| 9 Jan 2026filed 13 Jan 2026 | LSTA Lisata Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 9 Jan 2026filed 13 Jan 2026 | LSTA Lisata TherapeuticsBiotechnology | SEC FORM 4 Code A | —81,000 at $0.00 | filing |
| 9 Jan 2026filed 13 Jan 2026 | LSTA Lisata TherapeuticsBiotechnology | SEC FORM 4 Code F | $21K10,503 at $1.97 | filing |
| 9 Jan 2026filed 13 Jan 2026 | LSTA Lisata TherapeuticsBiotechnology | SEC FORM 4 Code F | $21K10,515 at $1.97 | filing |
| 9 Jan 2026filed 13 Jan 2026 | LSTA Lisata TherapeuticsBiotechnology | SEC FORM 4 Code F | $24K12,224 at $1.97 | filing |
| 9 Jan 2026filed 13 Jan 2026 | LSTA Lisata TherapeuticsBiotechnology | SEC FORM 4 Code F | $15K7,854 at $1.97 | filing |
| 10 Jan 2025filed 13 Jan 2025 | LSTA Lisata TherapeuticsBiotechnology | SEC FORM 4 Code F | $12K3,106 at $3.73 | filing |
| 9 Jan 2025filed 13 Jan 2025 | LSTA Lisata Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 9 Jan 2025filed 13 Jan 2025 | LSTA Lisata TherapeuticsBiotechnology | SEC FORM 4 Code A | —81,000 at $0.00 | filing |
| 9 Jan 2025filed 13 Jan 2025 | LSTA Lisata TherapeuticsBiotechnology | SEC FORM 4 Code F | $36K9,414 at $3.80 | filing |
| 9 Jan 2025filed 13 Jan 2025 | LSTA Lisata TherapeuticsBiotechnology | SEC FORM 4 Code F | $42K10,925 at $3.80 | filing |
| 9 Jan 2025filed 13 Jan 2025 | LSTA Lisata TherapeuticsBiotechnology | SEC FORM 4 Code F | $27K7,017 at $3.80 | filing |
| 1 Oct 2024filed 2 Oct 2024 | LSTA Lisata TherapeuticsBiotechnology | SEC FORM 4 Code A | $170K58,000 at $2.93 | filing |
| 1 Oct 2024filed 2 Oct 2024 | LSTA Lisata TherapeuticsBiotechnology | SEC FORM 4 Code F | $79K26,964 at $2.93 | filing |
News
Lisata Therapeutics Appoints Jeff Farrow to Board of DirectorsLSTA · manilatimes.net · 14 Oct 2026Analyzing Lisata Therapeutics (NASDAQ:LSTA) & Praxis Precision Medicines (NASDAQ:PRAX)LSTA · tickerreport.com · 11 Oct 2026Lisata Therapeutics wins new US patent for pancreatic cancer drugLSTA · proactiveinvestors.com · 8 Oct 2026
0 headlines in the last 90 days name David J. Mazzo; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.